

References for Module 2

1. Transglucosidase improves the gut microbiota profile of type 2 diabetes mellitus patients: a randomized double-blind, placebo-controlled study, Makoto Sasaki^{1*}, Naotaka Ogasawara¹, Yasushi Funaki¹, Mari Mizuno¹, Akihito Iida¹, Chiho Goto², Satoshi Koikeda³, Kunio Kasugai¹ and Takashi Joh⁴, BMC Gastroenterology 2013, 13:81
2. Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon
3. Xiaolei Ze¹, Sylvia H Duncan¹, Petra Louis¹ and Harry J Flint¹, The ISME Journal (2012) 6, 1535– 1543;
4. Adhesion of Vibrio cholerae to Granular Starches 5. Hanan Gancz, Orly Niderman-Meyer,^{1,†} Meir Broza,² Yechezkel Kashi,^{1,*} and Eyal Shimoni¹,Appl Environ Microbiol. 2005 Aug; 71(8): 4850–4855.
6. Galacto-oligosaccharides and bowel function, Leena Niittynen,¹ Kajsa Kajander,^{2,3} and Riitta Korpela^{2,3,4} Scand J Food Nutr. 2007 Jun; 51(2): 62–66.
7. <http://www.theatlantic.com/health/archive/2015/06/gut-bacteria-on-the-brain/395918/>
8. Effects of the in vitro fermentation of oligofructose and inulin by bacteria growing in the human large intestine.Wang X¹, Gibson GR.J Appl Bacteriol. 1993 Oct;75(4):373-80.
9. Effect of Probiotics Supplementation on Bone Mineral Content and Bone Mass Density 10. Kolsoom Parvaneh, 1 Rosita Jamaluddin, 1 ,* Golgis Karimi, 1 and Reza Erfani 2 11. ScientificWorldJournal. 2014; 2014: 595962.
12. The Gastrointestinal Microbiome and Musculoskeletal Diseases: 13. A Beneficial Role for Probiotics an Prebiotics 14. Luis Vitetta ^{1,2,*}, Samantha Coulson ², Anthony W. Linnane ^{1,3} and Henry Butt ⁴ 15. Pathogens 2013, 2, 606-626;
16. Environmental and NSAID-enteropathy: dysbiosis as a common factor. 17. Syer SD¹, Wallace JL, Curr Gastroenterol Rep. 2014 Mar;16(3):377.
18. <http://aspirenaturalhealth.com/sulfur-and-sulphate-reducing-bacteria-another-piece-in-the-puzzle-post-149-by-dr-tim-gerstmar-3262012/>
19. Dietary fructooligosaccharides and potential benefits on health.Sabater-Molina M¹, Larqué E, Torrella F, Zamora S.J Physiol Biochem. 2009 Sep;65(3):315-28.
20. Osteoporosis, inflammation and ageing, Lia Ginaldi,corresponding author¹ Maria Cristina Di Benedetto,¹ and Massimo De Martinis, Immun Ageing. 2005; 2: 14.
21. Bone loss in inflammatory disorders, R Hardy and M S Cooper, Journal of Endocrinology 2009,
22. Valyshev AV, Kirillov VA, Kirillov DA, Bukharin OV. The effect of inulin on the biological properties of enterobacteria. Zh Mikrobiol Epidemiol Immunobiol. 2000 Jan-Feb;(1)79-80.
23. Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: Part II – contemporary contextual research, Alison C Bested¹, Alan C Logan²Gut Pathogens 2013, 5:3

24. High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients. Frémont M, Coomans D, Massart S, De Meirleir K. *Anaerobe*. 2013 Jun 19. pii: S1075-9964(13)00092-9.
25. Insulin-sensitizing effects of dietary resistant starch and effects on skeletal muscle and adipose tissue metabolism^{1,2,3} M Denise Robertson et al, *Am J Clin Nutr* September 2005
26. Resistant Starch from High-Amylose Maize Increases Insulin Sensitivity in Overweight and Obese Men^{1,2,3}, Kevin C. Maki⁴ et al, *J. Nutr.* April 1, 2012
27. Cellulase production from *Aspergillus niger* MS82: effect of temperature and pH., Sohail M, Siddiqi R, Ahmad A, Khan SA., Department of Microbiology, University of Karachi, Karachi 75270, Pakistan *N Biotechnol.* 2009 Sep;25(6):437-41.
28. Cellulase enzyme from *Aspergillus niger*., Kassim EA. *Microbiol Immunol.* 1982;26(6):449-54.
29. Production of phytase (myo-inositolhexakisphosphate phosphohydrolase) by *Aspergillus niger* van Teighem in laboratory-scale fermenter, Vats P, Sahoo DK, Banerjee UC, Biochemical Engineering Research and Process Development Center, Institute of Microbial Technology, Sector 39-A, Chandigarh-160 036, India, *Biotechnol Prog.* 2004 May-Jun;20(3):737-43.
30. High level phytase production by *Aspergillus niger* NCIM 563 in solid state culture: response surface optimization, up-scaling, and its partial characterization. Bhavsar K, Kumar VR, Khire JM. NCIM Resource Center, National Chemical Laboratory, Pune, 411 008, India. *J Ind Microbiol Biotechnol.* 2011 Sep;38(9):1407-17. doi: 10.1007/s10295-010-0926-z. Epub 2010 Dec
24. 31. Acrylamide in Foods: A Review and Update¹, Amy H. Simonne and Douglas L. Archer², EDIS Publication #FCS8759 University of Florida
32. <http://sahlgrenska.gu.se/english/research/news-article//an-altered-gut-microbiota-can-predictdiabetes.cid1172716>
33. Obesity, Diabetes, and Gut Microbiota, The hygiene hypothesis expanded? Giovanni Musso, MD¹, Roberto Gambino, PHD² and Maurizio Cassader, *Diabetes Care* October 2010 vol. 33 no. 10 2277-2284
34. Obesity in the United States – Dysbiosis from Exposure to Low-Dose Antibiotics?, Lee W. Riley,^{1,*} Eva Raphael,¹ and Eduardo Faerstein², Fro J. G. M. Markle, D. N. Frank, S. MortinToth, C. E. Robertson, L. M. Feazel, U. Rolle-Kampczyk, M. von Bergen, K. D. McCoy, A. J. Macpherson, J. S. Danska. Sex Differences in the Gut Microbiome Drive HormoneDependent Regulation of Autoimmunity. *Science, 2013 Public Health.* 2013; 1: 69.
35. Microbiota associated with type 2 diabetes and its related complications, Yong Zhang, Heping Zhang, *Food Science and Human Wellness*, Volume 2, Issues 3–4, September–December 2013, Pages 167–172
36. Commentary Lipid Metabolism by Gut Microbes and Atherosclerosis, Joseph Loscalzo, *Circulation Research.* 2011; 109: 127-129.
37. Gut Flora Metabolism of Phosphatidylcholine Promotes Cardiovascular Disease, Wang et al *Nature.* 2011;472:57–63

38. Lactic acid bacteria affect serum cholesterol levels, harmful fecal enzyme activity, and fecal water content. Lee do K1, Jang S, Baek EH, Kim MJ, Lee KS, Shin HS, Chung MJ, Kim JE, Lee KO, Ha NJ. *Lipids Health Dis.* 2009 Jun 11;8:21.
39. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. Smits HH1, Engering A, van der Kleij D, de Jong EC, Schipper K, van Capel TM, Zaat BA, Yazdanbakhsh M, Wierenga EA, van Kooyk Y, Kapsenberg ML. *J Allergy Clin Immunol.* 2005 Jun;115(6):1260-7.
40. Probiotics for the prevention of *Clostridium difficile*-associated diarrhea in adults and children. Goldenberg JZ1, Ma SS, Saxton JD, Martzen MR, Vandvik PO, Thorlund K, Guyatt GH, Johnston BC. *Cochrane Database Syst Rev.* 2013 May 31;5:CD006095.
41. Glucosinolates: bioavailability and importance to health. Johnson IT1, *Int J Vitam Nutr Res.* 2002 Jan;72(1):26-31.
42. Chemoprevention studies of the flavonoids quercetin and rutin in normal and azoxymethane-treated mouse colon. Yang K1, Lamprecht SA, Liu Y, Shinozaki H, Fan K, Leung D, Newmark H, Steele VE, Kelloff GJ, Lipkin M., *Carcinogenesis.* 2000 Sep;21(9):1655-60.
43. Potential of probiotics, prebiotics and synbiotics for management of colorectal cancer, Maya Raman, 1 Padma Ambalam, 2 , * Kanthi Kiran Kondepudi, 3 Sheetal Pithva, 4 Charmy Kothari, 2 Arti T. Patel, 5 Ravi Kiran Purama, 6 J.M. Dave, 7 and B.R.M. Vyas, *Gut Microbes.* 2013 May 1; 4(3): 181–192
45. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. J H Cummings et al, *Gut* 1987;28:1221-1227 doi:10.1136/gut.28.10.1221
46. Regulation of short-chain fatty acid production, Sandra Macfarlane¹ and George T. Macfarlane¹, *Proceedings of the Nutrition Society / Volume 62 / Issue 01 / February 2003*, pp 67-72
47. Colonic health: fermentation and short chain fatty acids. Wong JM¹, de Souza R, Kendall CW, Emam A, Jenkins DJ. *J Clin Gastroenterol.* 2006 Mar;40(3):235-43.
48. HM Hamer, D Jonkers, K Venema, S Vanhoutvin, FJ Troost, RJ Brummer. Review article: the role of butyrate on colonic function. *Alimentary Pharmacology and Therapeutics.* 2008, 27(104119).
49. Roberto Berni Canani, Margherita Di Costanzo and Ludovica Leone. The epigenetic effects of butyrate: potential therapeutic implications for clinical practice. *Clinical Epigenetics* 2012, 4:4.
<http://www.clinicalepigeneticsjournal.com/content/4/1/4>
50. Nagendra Singh, Muthusamy Thangaraju, Puttur D. Prasad, Pamela M. Martin, Nevin A. Lambert, Thomas Boettger, Stefan Offermanns, and Vadivel Ganapathy. Blockade of Dendritic Cell Development by Bacterial Fermentation Products Butyrate and Propionate through a Transporter (Slc5a8)-dependent Inhibition of Histone Deacetylases. *The Journal of Biological Chemistry.* Sept 2010. 285: 36 (27601-27609).
51. Propionate as a health-promoting microbial metabolite in the human gut, Elham Hosseini et al, *Jul 27, 2014*

52. Butyrate and Propionate Protect against Diet-Induced Obesity and Regulate Gut Hormones via Free Fatty Acid Receptor 3-Independent Mechanisms, Hua V. Lin , et al, PLOS, April 10, 2012 DOI: 10
53. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism, Gijs den Besten et al, The Journal of Lipid Research, 2013 54, 2325-2340.
54. Probiotics—compensation for lactase insufficiency^{1,2,3} Michael de Vrese, Anna Stegelmann, Bernd Richter, Susanne Fenselau, Christiane Laue, and Jürgen Schrezenmeir, Am J Clin Nutr February 2001 vol. 73 no. 2 421s-429s
55. Metchnikoff E. 1908. The Prolongation of Life, 1st edition. G.P. Putnam's Sons, NY.
56. Schaafsma G. 1996. State of the art concerning probiotic strains in milk products. IDF Nutrition Newsletter 5:23 – 24.
57. Gorbach S.L. 1996. The Discovery of Lactobacillus GG. Nutrition Today Vol. 31(6) (suppl.):2S – 4S.
58. Saloff-Coste C.J. 1997. Lactobacillus acidophilus. Danone World Newsletter No. 13.
59. Martini M.C., D. Kukiela, D. Savaiano. 1991. Lactose digestion from yogurt: influence of a meal and additional lactose. Am. J. Clin. Nutr. 53:1253 – 8.
60. Kuhn C., A. Titze, C.A. Lorenz. 1996. Are viable microorganisms essential for the enhancement of intestinal hydrolysis of lactose by the β -galactosidase of fermented milk products? IDF Nutrition Newsletter 5:38.
61. Martini M.C., G.L. Bollweg, M.D. Levitt, et al. 1987. Lactose digestion by yogurt β -galactosidase: influence of pH and microbial cell integrity. Am. J. Clin. Nutr. 45:432 – 436.
62. Schaafsma G. 1993. Lactose intolerance and consumption of cultured dairy products — a review. IDF Nutrition Newsletter 2:15 – 16.
63. Onwulata C.I., D.R. Rao, P. Vankineni. 1989. Relative efficiency of yogurt, sweet acidophilus milk, hydrolyzed-lactose milk, and a commercial lactase tablet in alleviating lactose maldigestion. Am. J. Clin. Nutr. 49:1233 – 1237. 64. Sanders M.E. 1994. Lactic acid bacteria as promoters of human health. In Functional Foods, ed. I. Goldberg, London: Chapman & Hall. 294 – 322
64. Intestinal mucosal tolerance and impact of gut microbiota to mucosal tolerance, Dmitry A. Chistiakov, Front Microbiol. 2014; 5: 781.
65. Maassen C. B., Claassen E. (2008). Strain-dependent effects of probiotic lactobacilli on EAE autoimmunity. Maassen C. B., Claassen E. (2008). Vaccine 26, 2056–2057. 10.1016/j.vaccine.2008.02.035
66. A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Ochoa-Repáraz J., Mielcarz D. W., Wang Y., Begum-Haque S., Dasgupta S., Kasper D. L., et al. (2010). Mucosal Immunol. 3, 487–495. 10.1038/mi.2010.29
67. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Wu H. J., Ivanov I. I., Darce J., Hattori K., Shima T., Umesaki Y., et al. (2010)., Immunity 32, 815–827. 10.1016/j.immuni.2010.06.001

68. Cross-Talk between Probiotic Bacteria and the Host Immune System¹, Blaise Corthésy³, H. Rex Gaskins⁴, and Annick Mercenier, © 2007 American Society for Nutrition
69. Cytochrome P450 enzymes involved in the metabolic pathway of the histamine 2 (H₂)-receptor antagonist roxatidine acetate by human liver microsomes. Sasaki M¹, Nakayama M, Numazawa S, Oguro T, Honma S, Iwamura S, Tsukamoto K, Yoshida T. *Arzneimittelforschung*. 2001;51(8):651-8.
70. Gut Microbiota-Derived Short-Chain Fatty Acids, T Cells, and Inflammation, Chang H. Kim, corresponding author Jeongho Park, and Myunghoo Kim, *Immune Netw*. 2014 Dec; 14(6): 277–288. *Rev Esp Enferm Dig*. 2006 Jun;98(6):460-72., Kupffer cells and alcoholic liver disease. Cubero FJ¹, Nieto N.
71. Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. Breous E¹, Somanathan S, Vandenberghe LH, Wilson JM. *Hepatology*. 2009 Aug;50(2):612-21. doi: 10.1002/hep.23043.
72. Liver disease: Kupffer cells regulate the progression of ALD and NAFLD, Katherine Smith, *Nature Reviews Gastroenterology and Hepatology* 10, 503, Sept 2013
73. Probiotic yogurt effects on intestinal flora of patients with chronic liver disease. Liu JE¹, Zhang Y, Zhang J, Dong PL, Chen M, Duan ZP, *Nurs Res*. 2010 Nov-Dec;59(6):426-32
74. Kefir improves fatty liver syndrome by inhibiting the lipogenesis pathway in leptin-deficient ob/ob knockout mice, *Int J Obes (Lond)*. 2014 Sep;38(9):1172-9.
75. Gut Microbiota and Inflammation, Asa Hakansson and Goran Molin, *Nutrients*. 2011 Jun; 3(6): 637–682.
76. *Lactobacillus plantarum* NRIC1832 enhances IL-10 production from CD4⁺ T cells in vitro. Noguchi S¹, Hattori M, Sugiyama H, Hanaoka A, Okada S, Yoshida T. *Biosci Biotechnol Biochem*. 2012;76(10):1925-31. Epub 2012 Oct 7
77. Deconjugation of bile acids by intestinal lactobacilli., Gilliland SE, Speck ML, *Appl Environ Microbiol*. 1977 Jan;33(1):15-8.
78. *Lactobacillus* species prevents colitis in interleukin 10 gene-deficient mice. Madsen KL¹, Doyle, *Gastroenterology*. 1999 May;116(5):1107-14.
79. Jacobs BP, Dennehy C, Ramirez G, et al. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. *Am J Med*. 2002;113:506-515. Abstract
80. Lipopolysaccharide Animal Models for Parkinson's Disease, Mei Liu and Guoying Bing, Volume 2011 (2011), Article ID 327089, 7 pages
81. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases--a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. *Am J Gastroenterol*. 2005;100:2583-2591. Abstract

Lipopolysaccharide-induced liver apoptosis is increased in interleukin-10 knockout mice Jian Zhong et al, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Volume 1762, Issue 4, April 2006, Pages 468–477

Rambaldi A, Jacobs B, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev. 2005;2:CD003620.

Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev. 2007;4:CD003620.